Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.10 +0.85%

+$0.15 today

Market cap
$1.54B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.79M

Average 1.74M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$249.47M

FY 2025 · Annual

Investing Cash Flow

$147.85M

FY 2025 · Annual

Financing Cash Flow

$238.64M

FY 2025 · Annual

-50.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Net Income(117.19M)(180.36M)(143.95M)(193.57M)(264.46M)
Depreciation & Amortization6.08M10.81M13.65M16.43M18.86M
Deferred Income Tax00000
Stock-Based Compensation15.8M28.13M33.67M33.93M37.97M
Change in Working Capital9.11M(19.02M)20.12M(18.4M)(31.6M)
Accounts Receivables(6M)6M000
Inventory6.77M0000
Accounts Payables1.59M85K1.61M5.21M(630K)
Other Working Capital6.75M(25.11M)18.51M(23.61M)(30.97M)
Other Non-Cash Items1.83M636K(4.87M)(10.97M)(10.23M)
Operating Cash Flow(84.37M)(159.81M)(81.37M)(172.58M)(249.47M)
Capital Expenditures(5.66M)(12.24M)(8.4M)(9.27M)(14M)
Acquisitions (Net)102.59M(39.44M)000
Purchases of Investments(348.5M)(239.37M)(246.33M)(707.95M)(455.69M)
Sales of Investments245.91M278.81M323.04M459.51M617.54M
Other Investing Activities(102.59M)39.44M000
Investing Cash Flow(108.25M)27.2M68.3M(257.71M)147.85M
Debt Repayment00000
Common Stock Issued150.16M19.4M3.22M478.5M238.64M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.73M97.79M07.17M0
Financing Cash Flow153.88M117.19M3.22M485.67M238.64M
Effect of Forex Changes0000(67K)
Net Change in Cash(38.73M)(15.42M)(9.85M)55.37M137.03M
Free Cash Flow(90.03M)(172.05M)(89.77M)(181.86M)(263.47M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$264.5M
+ D&A$18.9M
+ Stock-Based Comp$38.0M
+ Deferred Tax$0
- Working Capital-$31.6M
- Other Non-Cash-$10.2M
= Operating Cash Flow-$249.5M
- Capex-$14.0M
= Free Cash Flow-$263.5M

Analysis

FY2025 free cash flow is -$263.5M. FCF conversion is 99.6% of net income. Operating cash flow was -$249.5M, with capex of -$14.0M. The largest bridge item is Stock-Based Comp at $38.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 5, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
8-KCurrent reportNov 3, 2026
4Statement of changes in beneficial ownershipNov 2, 2026

Does NRIX generate free cash flow?

Nurix Therapeutics, Inc. (NRIX) generated -$263.47M of free cash flow in fiscal 2025.

How much operating cash flow does NRIX produce?

Operating cash flow was -$249.47M, before capital expenditures of $14.00M.